Teva has lowered its 2017 guidance on the back of higher-than-expected generic price erosion and lower-than-expected Copaxone sales due to competition.
Particulate problems in sterile injectables and poor aseptic techniques landed Pfizer with a US FDA warning letter at a former Hospira facility in Kansas.
Teva has aggressively defended its market share for its blockbuster Copaxone says Momenta, six months after marketing partner Sandoz launched the first generic version in the US.
in-PharmaTechnologist.com's periodic round-up of developments in
the field of pharmaceutical facilities includes news of two
environmental fines, MHRA plant approval and a strike at Teva.
Drug delivery specialist Antares Pharma has landed its fourth deal
with Israeli generics behemoth Teva, this time to develop a novel
pen injector for two Teva products.